Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. Elghetany MT . True histiocytic lymphoma: is it an entity? Leukemia 1997; 11: 762–764.

    Article  CAS  Google Scholar 

  2. Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 2002; 41: 1–29.

    Article  CAS  Google Scholar 

  3. Ralfkiaer E, Delsol G, O'Connor NT, Brandtzaeg P, Brousset P, Vejlsgaard GL et al. Malignant lymphomas of true histiocytic origin. A clinical, histological, immunophenotypic and genotypic study. J Pathol 1990; 160: 9–17.

    Article  CAS  Google Scholar 

  4. Soslow RA, Davis RE, Warnke RA, Cleary ML, Kamel OW . True histiocytic lymphoma following therapy for lymphoblastic neoplasms. Blood 1996; 87: 5207–5212.

    CAS  PubMed  Google Scholar 

  5. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274–1276.

    Article  CAS  Google Scholar 

  6. Bessmertny O, Pham T . Thalidomide use in pediatric patients. Ann Pharmacother 2002; 36: 521–525.

    Article  Google Scholar 

  7. Baidas S, Tfayli A, Bhargava P . Thalidomide: an old drug with new clinical applications. Cancer Invest 2002; 20: 835–848.

    Article  CAS  Google Scholar 

  8. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950–1961.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité Protégée A, Hôpital Jeanne de Flandre, Lille, France

    J H Dalle, P Leblond, B Nelken & F Mazingue

  2. Service d'Anatomie Pathologique, Hôpital Calmette, Lille, France

    A Decouvelaere

  3. Unité de Greffes Médullaires, Service de Maladie du Sang, Hôpital Claude Huriez, Lille, France

    I Yakoub-Agha

  4. Laboratoire d'hématologie, Hôpital Calmette, Lille, France

    C Preudhomme

Authors
  1. J H Dalle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Leblond
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Decouvelaere
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Preudhomme
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Nelken
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Mazingue
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dalle, J., Leblond, P., Decouvelaere, A. et al. Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL. Leukemia 17, 2056–2057 (2003). https://doi.org/10.1038/sj.leu.2403075

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403075

  • Springer Nature Limited

This article is cited by

Search

Navigation